In the News

Read the latest about us

Modus Therapeutics granted two European Patents

STOCKHOLM, SWEDEN – 21 February  2018: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that the European Patent Office has granted to the Company two European patents. Modus has been granted a substance patent for its development compound sevuparin, […]

‘This could be the next $1 billion drug’

Drugmakers have had to confront patient distrust of the medical system and the system’s marginalization of sickle cell patients, reports Marketwatch. Read the full article, featuring interview with Modus Therapeutics Chief Executive Ellen Donnelly.

Series A boost for Swedish biotech’s SCD treatment

Modus Therapeutics closed SEK 140M (€13.5M) in Series A financing to complete a Phase II study testing its sickle cell disease drug and to prepare for further clinical trials. Read full story here.

SCD influencers come together at 7th Annual SCD Therapeutics Conference

Healthcare Providers, Patient Advocates and Policy Makers Will Discuss Issues Impacting  SCD Community During National SCD Awareness Month, reports Nasdaq. Read full story here.